Latest instructions: Can Mobosetinib be covered by medical insurance in 2024?

Mobocertinib demonstrated clinically meaningful and durable responses in patients with locally advanced or metastatic EGFR exon 20 insertion+ non-small cell lung cancer and is now the first and only treatment available for this patient population in China. Mobosetinib is an oral tyrosine kinase inhibitor designed to target exon 20 insertions. Full approval for this indication may depend on verification of clinical benefit in confirmatory trials.

This approval is based on results from the platinum-pretreated population of mobosertinib's Phase 1/2 trial, which included 114 patients with EGFR exon 20 insertion+ NSCLC who had previously received platinum-based therapy and received the 160 mg dose. The results showed that the confirmed ORR of each IRC was 28%, the median DoR of each IRC was 15.8 months, the median overall survival (OS) of each IRC was 20.2 months, and the median progression-free survival (PFS) was 7.3 months. The most common treatment-related adverse reactions were diarrhea, rash, paronychia, and decreased appetite.

MobosetinibThe original drug is currently on the market in China and has not yet been included in the medical insurance.It is still unknown whether it will be included in the medical insurance in 2024. The common specifications currently sold are 40mg*112 tablets per box with a price of 40,000 The price is very high at about RMB 7,000. The Hong Kong version of the original drug Specifications 40mg*30 capsules per box is priced at more than RMB 7,000 (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. Its pharmaceutical ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory 40mg*120 pills per box may be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.